Related Experiment Video
Updated: May 30, 2026

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
Reviewing non clinical data for a granulocyte colony stimulatory factor product: experience in Brazil
1Head of Efficacy and Safety Evaluation Office, National Health Surveillance Agency (ANVISA), SIA Trecho 5, Brasilia-DF, Brazil. laura.castanheira@anvisa.gov.br
Abstract:
Non clinical studies are one of the requirements for the Brazilian National Regulatory Authority, ANVISA, for licensing a similar biotherapeutic product. During the WHO/KFDA workshop on implementing WHO guidelines on evaluating similar biotherapeutic products (SBP) in Seoul, Republic of Korea, the Brazilian experience with the non clinical studies of a Granulocyte Colony Stimulatory Factor (G-CSF), filgrastim, was presented. The applicant presented a reduced non clinical data package, but the key studies with relevant species were conducted and the non-clinical studies were considered sufficient for approval. Using the comparability exercise, these studies were taken together with the appropriate quality and clinical packages presented.
Related Concept Videos
Bioequivalence studies: Biowaivers
Clinically Relevant Drug Product Specifications: Methods of Establishment
Clinical Trials: Overview
Preclinical Development: Overview
Bioavailability Study Design: Healthy Subjects Versus Patients
Regulation of Hematopoietic Stem Cells
